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Enhanced negative feedback sensitivity of the
hypothalamus-pituitary-adrenal axis in chronic myogenous facial
pain 
Abstract
Dysregulations of the hypothalamus-pituitary-adrenal (HPA) axis, as a physiological substrate of stress,
have been observed in patients with different stress-related and chronic pain disorders. In this study, we
investigated possible dysregulations of the HPA axis in patients with masticatory muscles pain. In 20
patients with myogenous facial pain and 20 healthy controls, awakening cortisol responses, i.e.cortisol
rise in the first hour after awakening, as well as a short circadian free cortisol profile, i.e. four cortisol
samples over 12h during the day, were assessed before and after administration of 0.5mg
dexamethasone. Results: In comparison to controls, chronic myogenous facial pain patients showed
enhanced and prolonged suppression of cortisol after the administration of 0.5mg dexamethasone.
Unstimulated cortisol response (before dexamethasone-intake) to awakening and cortisol levels during
the day did not differ between the groups. Dysregulation in terms of enhanced negative feedback
suppression exists in chronic myogenous facial pain. These results are in line with a multifactorial
etiology of chronic facial pain, shifting the perspective away from a local towards a more central
etiology with dysregulations in the stress and pain modulating system.
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Introduction 
 
Chronic facial pain is most often caused by a myoathropathy (MAP) of the masticatory system in 
particular by a myogeneous form. In a minority of 10-15% of the patients, the facial pain is associated 
to high pain-related disability and high rates of psychosocial distress so that these patients are to be 
considered as chronic pain patients (Von Korff et al., 1988,Dworkin and Massoth, 1994,Palla, 2006). 
Although the exact underlying pathophysiology of chronic myogeneous facial pain is poorly 
understood, there is growing evidence for a multifactorial etiology (Suvinen et al., 2005). 
Many patients report stressful life-events at the onset or during their painful state (Aghabeigi et al., 
1992) and there is a substantial overlap between a chronic myoarthropatic pain and other stress related 
conditions like fibromyalgia and tension type headache (Aaron and Buchwald, 2001,Macfarlane et al., 
2002,Glaros et al., 2007,Leblebici et al., 2007) as well as irritable bowel syndrome, chronic interstitial 
cystitis and premenstrual syndrome (Korszun et al., 1998). A physiological substrate of stress is 
constituted by dysregulations of the hypothalamus-pituitary-adrenal (HPA) axis, which have been 
observed in patients with chronic pain and fatigue disorders such as chronic fatigue syndrome and 
fibromyalgia (Parker et al., 2001), whiplash-associated disorder (Gaab et al., 2005), chronic pelvic 
pain (Heim et al., 1998), low back pain (Griep et al., 1998), irritable bowel syndrome (Bohmelt et al., 
2005) as well as in persons exposed to chronic or traumatic stress (Yehuda et al., 1993,Meinlschmidt 
and Heim, 2005). In patients with these chronic pain and fatigue symptoms as well as in the 
traumatized persons reduced activity and / or enhanced negative feedback sensitivity of the HPA-axis 
was found. In other terms for patients with these chronic somatic symptoms there is accumulating 
evidence of a basal hypocortisolism and an altered cortisol response to stress challenge (Parker et al., 
2001; Tanriverdi et al., 2006). 
The low dose (0.5 mg) dexamethasone suppression test (DST) selectively assesses the negative 
feedback sensitivity of the HPA axis on the level of the pituitary gland (Yehuda et al., 1993). 
Dexamethasone mainly suppresses HPA-axis functioning via hypophyseal pathways since it does not 
readily cross the blood-brain-barrier (De Kloet, 1997). The low dose DST has been shown to be of 
diagnostic value in depression, post traumatic stress disorders, chronic pain and fatigue syndromes 
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(Hunt et al., 1991,Yehuda et al., 1993,Heim et al., 1998),(Gaab et al., 2002,Gaab et al., 2005). Up to 
date only a few studies investigated the role of HPA hormones in MAP patients under natural 
(Korszun et al., 2002) and experimental conditions (Jones et al., 1997,Yoshihara et al., 2005). The aim 
of this study was therefore to perform the DST in patients with chronic myogeneous facial pain, the 
hypothesis being that this group of patients has a dysregulation of the HPA axis compared to healthy 
controls. This could help to clarify the etiology of chronic myogeneous facial pain.  
 
4 
Methods 
 
Subjects 
20 patients (3 men, 17 female, mean age 35.2) with chronic myogeneous facial pain, recruited from a 
population of patients seeking treatment at the orofacial pain clinic were included in the patient group. 
20 controls (3 men, 17 female, mean age 37.0) were selected from a pool of healthy, pain-free subjects 
recruited from an unselected general population and that had been used as controls also in a previous 
study (Gaab et al., 2002,Gaab et al., 2005). None of the controls had reported facial pain in the 
preceding 6 months and never had received treatment for a MAP. These controls were matched by 
age, gender and body mass index (BMI). All subjects filled out a written informed consent form. The 
study was approved by the Ethical Committee of the Medical Council of the Canton of Zurich. The 
recruitment of the myogeneous pain patients consisted of two consecutive steps: First, patients with a 
diagnosis of myoarthropathic pain were informed about the study goal. Interested subjects in the age 
range 18-60 years, fluent in German language and with facial pain were scheduled for a clinical 
examination by three reliable, calibrated dentists in order to select patients with myogeneous facial 
pain according to the the RDC/TMD (Dworkin and LeResche, 1992), i.e. (1) a report of pain in the 
jaw, temples, face, preauricular area, or inside the ear at rest or during function and (2) tenderness to 
palpation of three or more of the 14 examined muscle sites (see below), with at least one tender point 
on the painful side. At least two of the three diagnoses had to coincide. The presence of TMJ arthralgia 
and of a painless disc displacement with reduction did not lead to exclusion. 
Exclusion criteria for all study participants including the controls were: A diagnosis of functional 
somatic disorders, pregnancy, lactation, drug addiction, acute injuries as well as inhalative or systemic 
treatment with glucocorticoids that were addressed by means of an interview and a check-list. Further 
exclusion criteria were a current psychiatric diagnosis of a major psychiatric disorder (psychotic 
disorder, bipolar disorder, major depressive disorders, anxiety disorders, post-traumatic stress 
disorder, eating disorder, suicidality), use of antidepressants, anxiolytic, antibiotic, antihypertensive or 
steroid medication. These exclusion criteria were chosen in order to control for possible main effects 
of psychiatric disorders and medication on dependent variables. Occasional medication of NSAIDs 
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was accepted (and reported by 3 patients) as NSAIDs did’t alter the cortisol response on 
experimentally induced stress (Kudielka et al., 2008). 
 
Clinical examination 
The clinical examination, which was performed only on patients, followed the protocol described in 
the RDC/TMD (Dworkin and LeResche, 1992). The clinical examination included measurement of 
active and passive maximum opening, of active protrusion and laterotrusion, palpation and 
auscultation of the TMJ area and palpation of masticatory muscles. In contrast to the RDC criteria, 
only seven muscle sites per side were examined, i.e. the anterior, medial and posterior portion of the 
temporal muscle, the insertions of the temporal and medial pterygoid muscles, the superficial and deep 
masseter. The lateral pterygoid muscle was not palpated, as it is inaccessible to palpation (Stratmann 
et al., 2000,Turp and Minagi, 2001). Pressure palpation was standardized at 10 N/cm2 for extraoral 
muscles and 5 N/cm2 for the joints and the intraoral sites. A muscle was considered tender to palpation 
if the subject reported pain on palpation or the palpation elicited a blinking of the eyelids or a 
withdrawal reflex.  
 
Psychological evaluation 
All patients and controls were screened for psychiatric disorders using a short screening questionnaire 
(Wittchen and Pfister, 1997) and interviewed by clinical psychologists (JG or UG) to ensure the 
absence of exclusion criteria (vide supra) for participating in the study. All subjects completed a 
battery of questionnaires, including the German version of the Hospital Anxiety and Depression Scale-
German Version (HADS-D, (Zigmond and Snaith, 1983), the Fatigue Scale (FS, (Chalder et al., 1993), 
and visual analogue scales (VAS; 0 = no pain, 100 = worst pain imaginable) to assess pain, sleep 
duration and sleep quality before, during, and after sampling days.  
 
Cortisol assessment and biochemical analysis 
In order to assess the salivary free cortisol level saliva was collected at home by means of Salivettes 
(Sarstedt, Rommelsdorf, Germany). Subjects had to chew on a cotton salivette during a 1-min period 
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according to the manufacturer’s instructions. They had to collect samples on two consecutive days, 
allowing the assessment of the variation of the cortisol levels after awakening (cortisol awakening 
response) and over the day (short circadian cortisol profile). 
For the assessment of the cortisol awakening response samples were obtained immediately after 
awakening and 15, 30, 45 and 60 min thereafter. The subjects had to remain lying in bed for the first 
15 min. and not to have breakfast or brush the teeth during the first hour after awakening in order to 
avoid false high cortisol values due to plasma exudates from minor bleeding in the oral cavity. For the 
measurement of the short circadian cortisol profile four additional saliva samples were collected at 
8.00, 11.00, 16.00 and 20.00 o’clock. However, as subjects were free to wake up according to their 
normal schedule, the collection time for the first sample could vary individually. Subjects were asked 
not to eat or drink for 30 min before taking these four samples. In conclusion, each subject collected 
18 samples, 9 per day. 
In order to assess a possible dysregulation of the HPA axis subjects and patients took an oral dose of 
0,5 mg dexamethasone (Merck, Germany) at 11.00 p.m. on the first day.  
The saliva samples were stored in the refrigerator until completion of sampling and then brought to 
our laboratory where they were stored at -20°C until biochemical analysis took place. The salivary free 
cortisol was analyzed by using commercial chemiluminescence immunoassay (IBL, Hamburg, 
Germany). Inter- and intraassay coefficients of variation were below 10%. To reduce error variance 
caused by imprecision of the intraassay, all samples of one subject were analyzed in the same run. 
Collection and return of saliva sample as well as compliance with the protocol were supervised by 
study personnel. 
In order to calculate the sleep duration subjects had to record bed and awakening times. 
 
Statistical analysis 
Kolmogorov-Smirnov tests showed that salivary free cortisol data were not normally distributed. 
Calculating the log of cortisol values produced nearly normally distributed values so that Log-
transformed cortisol values were used in order to perform parametric statistical tests. However, the 
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results present means and standard deviations of the untransformed values. Data were also tested for 
homogeneity of variance using Levene´s test before statistical procedures were applied. 
ANOVAs for repeated measures were computed to analyze cortisol data, with clinical diagnosis as a 
grouping variable and time as the repeated measures factor. All reported results were corrected by the 
Greenhouse-Geisser procedure when assumptions of sphericity were violated. Correlations were 
computed by Pearson product-moment correlation. Possible differences in the psychological scores 
between the two groups were analyzed by Student’s t-test, ANOVA or MANOVA. 
For salivary cortisol levels after awakening, the areas under the curve with respect to ground (AUCg) 
was calculated as an indicator for the integrated cortisol responses (Pruessner et al., 1997). As several 
studies provided evidence that the cortisol awakening response (CAR) is a genuine repsonse to 
awakening and distinct from the circadian rise in HPA-activity in the early morning hours, we decided 
not to show the cortisol data as a function of clock time (Wilhelm I et al., 2007) 
AUCg for the short circadian cortisol profile were not computed due to the large time intervals 
between the cortisol measures. 
Based on the results of previous studies using a similar approach (Gaab et al., 2002,Gaab et al., 2005) 
it was calculated that a sample size of N = 40 was necessary in order to detect an expected multivariate 
effect size of f2=0.35 with a power ³ 0.90 and a = 0.05 (statistical software G-Power(•Buchner et al., 
1997). For all analyses, the significance level was a=5%. Unless indicated, all results shown are the 
mean ± standard error of means (SEM). 
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Results 
 
All patients fulfilled the criteria for a diagnosis of myogeneous facial pain according to the RDC/TMD 
(Dworkin and LeResche, 1992). Three of them had a diagnosis of myofacial pain (RDC/TMD 
category Ia) and seventeen had a diagnosis of myofacial pain with limited opening (RDC/TMD 
category Ib). Out of these, two had an additional diagnosis of arthralgia (RDC/TMD category IIIa) and 
five had a painfree disc displacement with reduction (RDC/TMD category IIa). The VAS mean pain 
intensity was 37.0, with a range of 8-75. 
Myogeneous pain patients did not differ from control subjects in age (Myogeneous pain patients: 
mean=35.2, range=19-60; controls: mean=37.0, range=21-59, F1,38=0.24, p=0.62), gender (3 men and 
17 females in both groups), and body mass index (Myogeneous pain patients: mean=22.54, 
range=16.80-29.30; controls: mean=23.253, range=18.15-32.66, F1,38=1.74, p=0.20).  
The mean pain duration was 71 months and the median was 48 months, with a range of 6 to 420 
months. With the exclusion of the only patient with a pain duration of 420 months the group mean 
pain duration was 52 months, with a range of 6-120 months. 
Symptoms duration was not associated with any psychometric scores or cortisol levels (pain duration-
HADS anxiety: r=0.12; -HADS depression: r=-0.28; -physical fatigue: r=-0.18: -mental fatigue: r=-
0.23, -AUCg day 1: r=-0.41; -AUCg day 2: r=-0.01; -mean cortisol levels day 1: r=0.002 -mean 
cortisol levels day 2: r=-0.04; all n.s.).  
 
Cortisol levels 
Day 1. The salivary free cortisol levels increased significantly in both groups after awakening (time 
effect: F2.4, 87.7=10.5, p<0.001), the differences between the two groups being statistically not 
significant (group by time effect: F2.4, 87.7=0.6, p=0.59, Figure 1). The cortisol levels significantly 
changed over the course of day 1 (time effect: F.2.5, 93.9=34.4, p<0.000), but cortisol levels over the 
short circadian profile did not differ between myogeneous pain patients and controls (group by time 
effect: F2.5, 93.9=1.6, p=0.21, Figure 2).  
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Day 2. In both groups the cortisol levels did neither increase significantly after awakening nor change 
during the day (time effects: F1.7, 62.4=0.4, p=0.71 and F1.6, 58.3=1.2, p=0.30, respectively). Due to the 
lack of significant changes over time, group effects rather than group by time effects were calculated. 
In both groups the intake of 0.5 mg of dexamethasone lead to a significant decrease in the cortisol 
levels both during the awakening response as well as the short circadian profile (Fig. 1 and 2). 
However, the decrease in the myogeneous pain patients group was statistically significantly larger than 
in the control group (group effects: awakening cortisol levels F1, 37=4.3, p=0.04, Fig. 1 and short 
circadian profile F1, 37=8.8, p=0.005, Fig. 2). These results were confirmed by group comparisons of 
the overall cortisol secretion (group effect: AUCg in nmol/time: myogeneous pain patients: 5.41 (1.8), 
controls: 22.07 (6.4), F1, 39=10.26, p=0.003, Figure 3).  
 
Compliance to protocol: All 20 myogeneous pain patients confirmed having taken dexamethasone. 
This is confirmed by the results as, in all subjects, an at least 50% reduction of the individual 
awakening AUCg and mean circadian cortisol levels on day 2 in comparison to day 1 was observed. 
The compliance was further confirmed by a second order interaction between cortisol measures x 
group x assessment day, with a significant interaction effect for awakening salivary cortisol (F2.5, 
91.7=9.6, p<0.000) and for the short circadian cortisol profile (F2.5, 91.7=21.2, p<0.000). 
As described above, all participants were informed in detail about the importance of adherence to the 
protocol. However we did not used any specific method or instrument for directly controlling sample 
time, i.e. electronic monitor caps or palm-pilots (Kudielka et al. Psychosomatic Med, 2003).  
 
Psychometric and sleep variables:  
Myogeneous pain patients exhibited significantly higher scores on depression, anxiety, physical 
fatigue and mental fatigue. However, depression scores remained below the cut-off score for clinical 
relevance , whereas anxiety levels were above. (Table 1). Also, myogeneous pain patients exhibited a 
lower quality of sleep than controls on both assessment days (Table 1). Sleep duration did not differ 
significantly between groups (Day 1: F1, 37=1.0, p=0.32, Myogeneous pain patients mean 6h45min 
(95% CI 6 h 6 min- 7 h 30 min), controls mean 7 h 20 min (95% CI 6 h 40 min-8 h 10 min), Day 2: F1, 
10 
37=3.2, p=0.08, Myogeneous pain patients mean 6 h 6 min (95% CI 5 h 30 min-6 h 45 min), controls 
mean 6 h 55 min (95% CI 6 h 15 min-7 h 35 min). 
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Discussion 
 
This study investigated the possibility of a dysregulation of the HPA axis in terms of activity, 
reactivity and negative feedback sensitivity in patients with chronic myogeneus facial pain. Main 
findings are: 1) Before intervention, cortisol levels on awakening and across the circadian rhythm did 
not differ between myogeneous facial pain patients and healthy matched controls. 2) After 
administration of 0.5mg dexamethasone, myogeneous facial pain patients showed significantly lower 
cortisol levels at all measurement points. 3) Myogeneous facial pain patients scored significantly 
higher in measures of psychological distress as evidenced in clinically elevated levels for anxiety, but 
not for depressive symptoms. This is in line with results of other studies on TMD patients finding very 
similar results with higher scores on anxiety then on depression (Jerjes W et al., 2007) 
Before intervention, all cortisol levels were inconspicuous in our sample. This finding contrasts to the 
report by Korszun and colleagues (Korszun et al., 2002), who found significant higher basal circadian 
cortisol levels in temporomandibular disorders (TMD) patients compared to controls. However, 
methodological differences between the studies need to be noted. The TMD patients examined by 
Korszun et al. (2002) had low pain intensity, and high depression scores. Our myogeneous facial pain 
patients group on the other hand was characterized by a moderate to high mean pain intensity level, 
but low mean depression score. The reported cortisol differences between their study and our study 
may be due to these differences, since the awakening cortisol responses are sensitive to the individual 
symptomatic profile (Ehlert et al., 2005). Two studies investigated the HPA axis reactivity of TMD 
patients to experimentally induced psychosocial stress. One reported an elevated cortisol response to a 
standardized stress paradigm in a subgroup of TMD patients compared to controls (Jones et al., 1997). 
These results were partly confirmed by a recent study, reporting higher cortisol stress responses in 
patients with myofacial pain in comparison to healthy controls (Yoshihara et al., 2005). However, it 
needs to be noted that these two studies examined cortisol responses to experimental induced stress in 
contrast to our approach that observed cortisol levels upon awakening and across the circadian rhythm. 
The different findings could thus be due to disparate underlying neuroendocrine processes (Herman 
and Cullinan, 1997).  
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Our finding that myogeneous facial pain patients showed significantly lower cortisol levels at all 
measurement points after administration of 0.5mg dexamethasone is indicative of an enhanced and 
persisting suppression of cortisol levels. Similar findings have been reported in other medically 
unexplained syndromes including chronic fatigue syndrome (Gaab et al., 2002), fibromyalgia (Griep et 
al., 1998, (Wingenfeld et al., 2007), chronic pelvic pain (Heim et al., 1998), chronic whiplash 
associated disorder  (Gaab et al., 2005) as well as psychiatric disorders with a predominance of 
somatic symptoms, such as atypical depression (Levitan et al., 2002). This stresses the need to 
consider etiologic similarities between these conditions (Barsky and Borus, 1999; Wessely et al., 
1999). 
However, it needs to be noted that the observed enhanced negative feedback sensitivity to 
dexamethasone did not lead to a reduced output of salivary cortisol after awakening or over the 
circadian rhythm. A similar pattern has been observed in some (e.g. Gaab et al., 2002), but not all 
medically unexplained syndromes (e.g. Wingenfeld et al., 2007 and Gaab et al., 2005). It remains 
unclear whether normal cortisol levels in the face of enhanced negative feedback sensitivity is either 
the result of a weak association between impaired glucocorticoid receptor-related negative feedback 
on the level of the pituitary and  assessed salivary cortisol levels or a result of adaptive processes at the 
level of the adrenal. Further studies are clearly needed to elucidate this matter. 
In case of a confirmation of the observed HPA axis dysregulations in patients with chronic 
myogeneous facial pain in further studies, with more sophisticated neuroendocrine procedures, 
assessment of the HPA axis dysregulations could serve as a important constituent of a 
multidimensional understanding of chronic myogeneous facial pain, shifting the perspective away 
from a local towards a more central etiology with dysregulations in the stress and pain modulating 
system (Lariviere and Melzack, 2000).  
There is evidence for generalized hyperalgesia in MAP patients and hormonal as well as neural 
mechanisms leading to hyperexcitability and amplification of the nociceptive inputs have been 
discussed (Sarlani and Greenspan, 2003). One possible mechanism leading to enhanced pain 
sensitivity may be a reduced release of corticotropin-releasing-hormone (CRH), since CRH seems to 
be involved in central as well as peripheral pain processing  (Lariviere and Melzack, 2000). 
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Interestingly the first human study on the CRH analgesic properties was done in dentistry: intravenous 
CRH administration lead to significantly less postoperative dental pain than with placebo (Hargreaves 
et al., 1987). However, this study did not assess CRH or other directly associated hormones, such as 
adrenocorticotropin hormone (ACTH).  
Some methodological shortcomings must be acknowledged. First: Previous studies has shown that 
objective compliance with protocol is lower than self-reported compliance especially when sampling 
period is over several days producing incorrect data particularly in the last sampling days. (Broderick 
JE, PNEC, 2003). As we did not use electronic monitor caps or palm-pilots, compliance to protocol by 
the participants may be lower than expected. Although our study time was only two days and correct 
data collection more probable we strongly recommend these techniques in further studies.  
Second: Dexamethasone bioavailability is considered to be important in interpreting cortisol 
suppression of dexamethasone. A study on depressed patients found a correlation between 
bioavailability of dexamethasone and cortisol suppression after dexamethasone intake, probably 
because of accelerated dexamethasone clearing. (Cassidy et al., 2000). However, in several studies 
using the low-dose-dexamethasone-test, no different dexamethasone levels have been found in plasma 
or saliva nor was there a correlation between cortisol and dexamethasone levels (e.g. (Goenjian et al., 
1996). Dexamethasone bioavailability may be influenced by age and body-mass-index but as we 
matched our groups with respect to these factors, we consider that possible differences in 
dexamethasone bioavailability could explain our results.  
In summary, the results showed that patients with chronic myogeneous facial pain have enhanced 
negative feedback sensitivity after the intake of a low dose of dexamethasone whereas the cortisol 
awakening response as well as the secretion of cortisol over the course of the day appear normal. 
These results are in line with a multifactorial etiology of chronic facial pain.  
This supports multidisciplinary treatment approaches for patients with chronic myogeneous facial pain 
similar to those used in other chronic pain disorders, including interventions for pain- and stress-
management.  
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TABLE 1. Psychometric characteristics of patients with myogeneous facial pain and healthy controls 
 
Questionnaire Scale Patients1 Controls1 Statistics 
Depression 4.6 (0.7) 0.8 (0.2) F=23.1, P<0.000 HADS 
Anxiety 9.5 (0.7) 2.1 (0.4) F=63.7, P=0.000 
Physical Fatigue 4.8 (0.5) 0.8 (0.3) F=209.0, P<0.000 FS 
Mental Fatigue 1.9 (0.3) 0.2 (0.2) F=268.0, P<0.000 
Pain2 37.0 (4.0) 5.9 (3.9) F=63.8, P<0.001 VAS day 1 
Sleep Quality3 28.4 (1.9) 5.5 (1.6) F=79.3, P<0.001 
Pain2 32.5 (3.9) 5.8 (4.2) F=51.5, P<0.001 VAS day 2 
Sleep Quality3 31.2 (1.6) 3.9 (1.3) F=74.2, P<0.001 
1 mean (SEM), 2 0-100 (no-worst pain imaginable), 3 0-100 (good-very bad sleep quality) 
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FIGURE 1. Awakening salivary cortisol levels before (top panel) and after (bottom panel) the 
administration of 0.5mg dexamethasone at 11 pm on Day 1 of patients with chronic myogeneous facial 
pain (n , N=20) and healthy controls (l , N=20). 
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FIGURE 2. Circadian salivary free cortisol levels before (top panel) and after (bottom panel) the 
administration of 0.5mg dexamethasone at 11 pm on Day 1 of patients with chronic myogeneous facial 
pain (n , N=20) and healthy controls (l , N=20). 
 
 
21 
patients controls
0
5
10
15
20
25
30
patients
controls
Day 2/post-DST
 
 
FIGURE 3. Area under the awakening cortisol response curve with respect to ground after the 
administration of 0.5mg dexamethasone at 11 pm on Day 1 of patients with chronic myogeneous facial 
pain (n , N=20) and healthy controls (l , N=20). 
 
